摘要:目的: 探討血清前白蛋白(prealbumin,PAB)、膽堿脂酶(cholinesterase,ChE)、總膽汁酸(total bile acid,TBA)在肝硬化中的檢測價值。 方法 :測定105例肝硬化患者和30例健康人的前白蛋白、膽堿脂酶、總膽汁酸活性及肝功能生化指標,并按ChildPugh分級進行比較。 結果 :肝硬化組前白蛋白含量、膽堿脂酶活性均較對照組顯著降低;按ChildPugh分級比較,肝硬化組前白蛋白含量在Child A級與對照組、B級與A級之間、在C級與B級之間差異有顯著性(Plt;001);膽堿脂酶活性在Child A級與對照組、B級與A級、C級與B級之間差異有顯著性(Plt;001)。總膽汁酸在Child B級與A級,C級與B級間有顯著差異性,在A級與對照組間差異無顯著性。 結論 :血清前白蛋白、膽堿脂酶在肝硬化早期評估中有很重要的價值,而總膽汁酸在肝硬化預后的判定中有重要價值。 Abstract: Objective: To evaluate the role of prealbumin (PAB), cholinesterase (ChE), and total bile acid (TBA) in evaluating liver reserve function in patients with liver cirrhosis. Methods : One hundred and five serum samples from patients with liver cirrhosis were detected in PAB, ChE, TBA and other biochemical markers. All patients were classified in accordance with ChildPugh scale. Results : For PAB, the differences among ChildPugh A, B, C and healthy group were statistically significant (t=1254, 1887, 2316) (Plt;001). For ChE, the differences among ChildPugh A, B, C and healthy group were statistically significant (t=1288, 0856, 1002) (Plt;001). For TBA, the differences among ChildPugh C group, B group and A group were statistically significant (t=0526, 1081)(Plt;001), the difference among ChildPugh A group and healthy group was not statistically significant (t=5615) (Pgt;005). Conclusion : PAB and ChE reflect liver reserve function earlier in patients with liver cirrhosis. The role of TBA is important in reflecting prognosis in patients with liver cirrhosis.
ObjectiveTo investigate the clinical value of small-for-size left lobe liver auxiliary partial orthotopic liver transplantation (APOLT) in the treatment of decompensated cirrhosis. MethodThe preoperative and postoperative clinical data of 4 patients who received small-for-size left lobe liver APOLT in 2023 were retrospectively described and analyzed. ResultsOne patient suffered metabolic liver disease cirrhosis and the other three suffered hepatitis B cirrhosis, all of whom presented with decompensated cirrhosis. Preoperative evaluation showed that the graft-to-recipient weight ratio was less than 0.6%. All recipients underwent left hemihepatectomy. The grafts were derived from living donors in 3 cases, from donation after citizen death in 1 case. After APOLT treatment, 4 patients and grafts survived, 1 patient experienced transplantation rejection and recovered after modified anti-rejection therapy. Three patients with hepatitis B cirrhosis were treated with nucleoside analogues and hepatitis B immunoglobulin, the hepatitis B virus DNA was negative at the end of follow-up, one of three patients with hepatitis B cirrhosis showed negative results for hepatitis B virus in the graft biopsy at month one after surgery. ConclusionsFrom the summary results of these cases, small-for-size left lobe liver APOLT can be used to treat decompensated cirrhosis. The application and popularization of this treatment regimen is expected to expand the donor pool and benefit more decompensated cirrhosis patients with lower Model for End-stage Liver Disease score.
【摘要】 目的 應用門冬氨酸鳥氨酸對肝性腦病的臨床療效及安全性進行觀察。 方法 2000年4月-2009年11月，將60例肝硬化肝性腦病患者分為對照組和治療組，對照組給予常規精氨酸治療，治療組在對照組基礎上加門冬氨酸鳥氨酸10 g/d，靜脈滴注，連續7 d。觀察治療前后神志變化、血清氨基轉移酶(ALT、AST)、血清白蛋白(ALB)等指標變化。 結果 治療組經門冬氨酸鳥氨酸治療后神志改變、ALT、AST明顯優于治療前（Plt;0.05）。 結論 門冬氨酸鳥氨酸治療肝性腦病療效確切，且對肝功能有改善作用，副反應小。【Abstract】 Objective To evaluate the clinical efficacy and safety of L-ornithine-L-aspartate treating the patients with hepatic encephalopathy. Methods Sixty patients with hepatic encephalopathy from April 2000 to November 2009 were randomly divided into treatment group and control group with 30 patients in each. The patients in the control group were treated with the routine therapy of arginine, while the ones in the treatment group were treated with L-ornithine-L-aspartate besides the routine therapy for one week injection (10.0 g dissolved in 5% glucose 250 mL by intravenous infusion once daily), the liver function and mind change were observed in all patients at the onset and one week after treatment respectively. Results One week after the treatment, the liver function (ALT, AST) and mind change of patients differed statistically significantly from that before the treatment (Plt;0.05). Conclusion L-ornithine-L-aspartate is effective for the patients with minimal hepatic encephalopathy, which could improve the liver function with little side effect.
ObjectiveTo discuss the clinical characteristics of liver cirrhosis in elderly patients.
MethodsWe retrospectively analyzed the clinical data of 67 patients (elderly group) with liver cirrhosis aged ≥60 treated between January 1998 and December 2010. Then, we compared these cases with another 72 liver cirrhosis patients (non-elderly group) aged<60.
ResultsThe incidence of jaundice, ascites and albumin deficiency in the elderly patients was significantly higher than that in the non-elderly patients (P<0.05). Complications in the elderly group were relatively more, including electrolyte imbalance, infections, gastrointestinal bleeding, hepatic encephalopathy, liver cancer, liver and kidney syndrome and liver and lung syndrome, and the incidence of these complications was all significantly higher than the non-elderly group (P<0.05) except the liver and kidney syndrome (P>0.05). The causes of liver cirrhosis in both groups were similar. The most common cause was hepatitis B virus infection, followed by chronic alcoholism, but in the elderly group, chronic alcoholism, cholestasis, poisoning from medicines and poisons and liver blood circulation disorders were more common than the non-elderly group (P<0.05); hepatitis B and non-alcoholic fatty hepatitis were more common in the non-elderly group than in the elderly group (P<0.05). The elderly group had more Child-Pugh class C cases (P<0.05), while there were more class A cases in the non-elderly group (P<0.05). Twenty-six patients died in the elderly group with a mortality rate of 38.8%; while only 13 died in the non-elderly group with a mortality rate of 18.1%. The difference of mortality rate was significant between the two groups (P<0.05). Common causes of death in the elderly group were infection, hepatic encephalopathy, and electrolyte disorders and gastrointestinal bleeding, while the common causes of death in the non-elderly group were gastrointestinal bleeding and electrolyte disorders.
ConclusionThe etiology, clinical manifestations and prognosis of liver cirrhosis in elderly patients differ from those in younger patients. We must pay more attention on treating complications of liver cirrhosis in elderly patients.
ObjectiveTo investigate the hotspots and frontiers and to reveal research trends of cirrhosis with portal vein thrombosis (PVT) by visual analysis.MethodsWe explored the distributions, key citations and research trends of articles on cirrhosis with PVT published from 1991 to 2020 by citation analysis, co-word analysis, and burst detection by information visual software CiteSpace.ResultsThe quantity of articles on cirrhosis with PVT had been increasing over time. The management of PVT remained the hotspots, while the efficacy and prognosis of anticoagulation of PVT as well as the risk factors and underlying mechanisms of PVT had been frontiers in recent years.ConclusionsAnticoagulation and risk factors have been hotspots and frontiers in recent years.
